Greenwich LifeSciences, Inc. stock is up 44.51% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 March’s closed higher than February. 100% of analysts rate it a buy.
Greenwich LifeSciences focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!